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a b s t r a c t
Simvastatin (SMV) has been shown to exhibit promising anti-inﬂammatory properties alongside its
classic cholesterol lowering action. We tested these emerging effects in a major thermal injury mouse
model (3rd degree scald, 20% TBSA) with previously documented, inﬂammation-mediated intestinal
defects. Neutrophil extracellular traps (NETs) inﬂammation measurement methods were used alongside
classic gut mucosa inﬂammation and leakiness measurements with exogenous melatonin treatment as a
positive control. Our hypothesis is that simvastatin has protective therapeutic effects against early
postburn gut mucosa inﬂammation and leakiness. To test this hypothesis, we compared untreated
thermal injury (TI) adult male mice with TI littermates treated with simvastatin (0.2 mg/kg i.p., TIþSMV)
immediately following burn injury and two hours before being sacriﬁced the day after; melatonin-
treated (Mel) (1.86 mg/kg i.p., TIþMel) mice were compared as a positive control. Mice were assessed for
the following: (1) tissue oxidation and neutrophil inﬁltration in terminal ileum mucosa using classic
carbonyl, Gr-1, and myeloperoxidase immunohistochemical or biochemical assays, (2) NETosis in
terminal ileum and colon mucosa homogenates and peritoneal and ﬂuid blood samples utilizing ﬂow
cytometric analyses of the surrogate NETosis biomarkers, picogreen and Gr-1, and (3) transepithelial gut
leakiness as measured in terminal ileum and colon with FITC-dextran and transepithelial electrical
resistance (TEER). Our results reveal that simvastatin and melatonin exhibit consistently comparable
therapeutic protective effects against the following: (1) gut mucosa oxidative stress as revealed in the
terminal ileum by markers of protein carbonylation as well as myeloperoxidase (MPO) and Gr-1
inﬁltration, (2) NETosis as revealed in the gut milieu, peritoneal lavage and plasma utilizing picogreen
and Gr-1 ﬂow cytometry and microscopy, and (3) transepithelial gut leakiness as assessed in the ileum
and colon by FITC-dextran leakiness and TEER. Thus, simvastatin exhibits strong acute anti-inﬂammatory
actions associated with marked decreases in gut tissue and systemic NETosis and decreased gut mucosa
leakiness.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
Accumulating evidence supports the emerging anti-inﬂammatory
actions of simvastatin andmelatonin alongside their classic roles in the
treatment of hyperlipidemia and jetlag, respectively [1–12]. Recently,
we have reported that melatonin suppresses neutrophil-mediated
major postburn gut inﬂammation [1]. The similarity of our melatonin
results to those of simvastatin actions reported in other systems
triggered our interest in examining the effect of simvastatin treatment
on postburn gut inﬂammation and leakiness.
The role of neutrophil hyperactivation in major postburn
gut barrier pathogenesis has been assessed by a wide range of
markers such as granulocyte-1 (Gr-1), myeloperoxidase (MPO),
elastase, nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase proteins (p47phox and p67phox), reactive oxygen species, and
intracellular calcium, alongside immunological factors such as
bactericidal/permeability-increasing protein (BPI), defensins, CD-
11b, -11c, and -18, IL-18 and chemokines cytokine-induced neutro-
phil chemoattractant (CINC) [1,13–21]. Aside from these biomar-
kers, our search for tools to assess simvastatin’s anti-inﬂammatory
actions led us neutrophil extracellular traps (NETs) especially
because they constitute a major aspect of neutrophil effector
function that also encompasses many of the aforementioned
markers [22–32]. Indeed, as neutrophil supramolecular fragments
that are able to entrap and kill pathogens, NETs have been shown to
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contain nuclear DNA alongside cytoplasmic granules, proteases
(MPO and elastase), and reactive oxygen species associated with
neutrophil’s oxidative burst.
Unfortunately, the powerful immune defense function of NETs,
aimed at combating the spread of pathogens and limiting the
spread of potentially harmful neutrophil byproducts, may occur at
the cost of collateral tissue damage associated with excessive
NETosis especially in cases of hyperinﬂammation encountered in
the major postburn gut mucosa milieu [33–36]. Mechanistically,
effects of NETosis may include immunomodulation, effector func-
tion, and intercellular signal transduction [34]. As such,
NETs appear to activate adaptive immunity by priming T-cells
thus resulting in a second wave of inﬂammation [36]. Such side
effects may explain the role of NETs in autoimmune diseases, such
as vasculitis, psoriasis, systemic lupus erythematosis (SLE), Felty’s
syndrome, and gout [24,25,33–36]. This is in addition to immu-
nosuppressed individuals where several components of NETs
(DNA, histones, and MPO) also act as autoantigens [34]. Similarly,
NETosis has been linked to vascular pathogenesis (thrombosis,
atherosclerosis, and preeclampsia) [34].
In recent works, the quantiﬁcation of NETs has been proposed
as diagnostic and prognostic inﬂammatory markers for sepsis
[26,27,29]. NETs are ideal as a marker for inﬂammation due to
their ability to traverse internal barriers and compartments as
circulating free DNA (cf-DNA), as well as the rapid kinetics of
NETosis [27,29–31]. Indeed, NETs have been found to be compar-
able and at times even better than classical inﬂammatory and
septic markers, which include total leukocyte count, C-reactive
protein (CRP), IL-6, and MPO [27,29].
As such, we hypothesize that NETs are the quintessential choice
as a diagnostic marker for postburn gut inﬂammation that may be
tested in multiple body ﬂuids and compartments to assess the
anti-inﬂammatory effects of drugs such as simvastatin. In this
investigation, we provide evidence for beneﬁcial effects of simvas-
tatin (0.2 mg/kg) treatment comparable to those of melatonin
(1.86 mg/kg) on the postburn inﬂammatory state of multiple body
compartments as well as gut leakiness. These simvastatin and
melatonin doses were developed and tested in our lab based on
several MSc thesis projects as well as clear anti-inﬂammatory
effects seen in previous published works using mouse models
[1,37].
2. Materials and methods
2.1. Thermal injury and treatment protocols
Male BALB/c mice weighing 25–30 g (Harlan laboratories,
Indianapolis, IN) were used in this work. All animal handling,
housing, feeding, and experimentation were in accordance with
Chicago State University’s Institutional Animal Care and Use
Committee (IACUC) approved protocols and with NIH guidelines
and based on our previously published protocols [1,17–21]. All
mice were acclimatized in the animal facility for at least one week
and were continually maintained under a 12-h light: 12-h dark
cycle (LD 12:12) with free access to water and standard mice chow
ad libitum. Mice were separated into four groups: control (CT),
thermal injury (TI), and TI with post treatment of either melatonin
(TIþMel) or simvastatin (TIþSMV). Thermal injury and sacriﬁce
were around Zeitgeber Time (ZT) 4 with ZT 0 being the onset of
the light period. Thermal injury was performed as described
previously [1,17–21]. Brieﬂy, mice were deeply anesthetized with
sodium pentobarbital (50 mg/kg, IP, and unresponsiveness to a
hind limb pinch) before shaving their dorsum then placing them in
a bottomless plastic mold to expose only 20% of their total body
surface area (TBSA) to scalding water (90–95 1C) for 10 s. Mice
were immediately blotted dry then resuscitated with 0.5 mL
normal saline intraperitoneal injection. Treatment groups received
intraperitoneal melatonin or simvastatin (Sigma-Aldrich, St. Louis,
MO) at doses of 1.86 mg/kg (TIþMel) and 0.2 mg/kg (TIþSMV)
immediately following injury and around 2 h before being sacri-
ﬁced based on published doses and protocols [1,10,12].
2.2. Specimen collection and preparation
Peritoneal lavage was induced by 4% thioglycolate (1 mL, IP)
injection 2 h before sacriﬁce [13]. Circulating blood was collected
transcardially upon chest opening under deep anesthesia (sodium
pentobarbital, 50 mg/kg, IP, and unresponsiveness to a hind limb
pinch) followed by immediate fresh collection of peritoneal lavage
and dissection of the terminal ileum. Blood and peritoneal lavage
samples were collected in heparinized syringes and tubes and set
on ice then immediately used for ﬂow cytometry and ﬂuorescent
microscopy. The terminal ileum and proximal colon segments
were gently ﬂushed with cold sterile phosphate buffered saline
(PBS) then cut in 1–3 cm segments that were either immediately
used fresh for transepithelial diffusion or electrical resistance,
prepared for ﬂow-cytometric and microscopic NETosis analyses,
carbonyl slot blotting, MPO colorimetric assay (see below), or
preserved in 4% paraformaldehyde ﬁxative at 4 1C for cryostat-
sectioning.
2.3. Gr-1 immunohistochemistry
Fixed ileum and colon segments were mounted in Neg-50
embedding solution (Richard-Allan Scientiﬁc, Kalamazoo, MI) on a
cryostat chuck for cut into 30 μm cross sections (HM 550 Cryostat,
Richard-Allan Scientiﬁc) and thaw-mounted on Superfrost-Plus
slides (Fisher Scientiﬁc, Hampton, NH) and stored at 20 1C until
use. Gr-1 immunohistochemistry was based on previously pub-
lished protocols [19]. Brieﬂy, cryostat sections were thawed for 10
min and sequentially passed through the following solutions (pH
7.4 and at room temperature, unless speciﬁed): PBS washing buffer
(3  3 min), blocking solution containing 0.1% normal goat serum
and 0.1% Triton-X 100 (1 h), primary antibody (rabbit anti-Gr1,
Sigma-Aldrich) diluted in blocking buffer at 1:1000 primary anti-
body (overnight at 4 1C), PBS washing buffer (33 min), second-
ary antibody (goat anti-rabbit IgG (for Gr-1) diluted 1:1500 in
blocking buffer (45 min), then PBS washing buffer (33 min)).
Immunostaining was processed for microscopic imaging with an
Eclipse TE2000-S Inverted Fluorescent Microscope (Nikon), cam-
era (Cool Snap ES, Photometric, Tucson, AZ), and Metamorph
software (Universal Imaging, Downingtown, PA) or EVOS ﬂuores-
cent digital microscopy.
2.4. Carbonyl slot blotting
Total protein was isolated from freshly homogenized terminal
ileum and colon mucosa scrapings processed with Ready Prep
Protein Extraction Kit (Bio-Rad, Hercules, CA) and then blotted as 5
μg samples onto a polyvinylidene diﬂuoride (PVDF) membrane
using Bio-Dot SF Microﬁltration Apparatus (Bio-Rad) in accordance
with previously published protocols [38]. The PVDF membrane
was processed for chemiluminescence by being sequentially
passed through the following solutions (pH 7.4 and at room
temperature, unless speciﬁed): 100 μg/mL 2.4-dinitrophenylhy-
drazine (DNPH) in 2 N hydrochloric acid (HCl) (5 min), 2 N HCl
washing solution (3  5 min), 100% methanol (7  5 min),
blocking solution that contained 5% non-fat dry milk in Tris-
buffered saline (1 h), monoclonal rabbit anti-carbonyl primary
antibody diluted 1:25,000 in blocking buffer (overnight at 4 1C),
washing solution that contained 1% non-fat dry milk in 0.1% TBS
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containing Tween 20 (TBST) (5  5 min), monoclonal horseradish
peroxide (HRP)-conjugated goat anti-rabbit secondary antibody
diluted 1:5000 in blocking buffer (1 h), then washing buffer.
Membranes were then incubated with enhanced chemilumines-
cence (ECL), ﬁlm exposed for chemiluminescence detection, then
imaged for densitometric measurement.
2.5. MPO colorimetric assay
Fresh ileum segments were processed for MPO Colorimetric
Assay based on previously published protocols [20]. Brieﬂy, they
were washed with Hank’s Balanced Salt Solution (HBSS) and
homogenized using the Brinkman tissue homogenizer in potas-
sium phosphate buffer (pH7.4) containing 2 mM phenylmethyl-
sulfonyl ﬂuoride (PMSF) for 20 s. The ileal homogenates were
centrifuged at 10,000 rpm for 30 min at 4 1C the resulting pellet
was further homogenized in 50 mM potassium phosphate buffer
(pH  6.0) containing 0.5% hexadecyltrimethyl-ammounium bro-
mide (HETAB) (Sigma) and 10 mM EDTA. The samples and a
standard (0–0.125 U recombinant human MPO) (Sigma) were
added to 0.5 mL of “MPO cocktail” consisting of 800 mM
potassium phosphate buffer (pH  5.4), 0.5% HETAB, and
1.6 mM 3,30,5,50-tetramethylbenzidine (TMB) (Sigma) at 37 1C.
The reaction was started with 0.3 mM H2O2 for 3 min and
ended with 1 mL of acetate buffer. The intensity of blue chromo-
gen in 1 mL of the reaction mixture with a maximum wavelength
of 655 nm was read on a Multiskan EX plate reader
(Thermo Scientiﬁc). The relative MPO activity (number of units/
mg of protein) was calculated from the plot of the standard MPO
units versus absorption. The protein in the ﬁnal sample
was estimated by Pierce BCA protein assay kit (Thermo Scientiﬁc,
West Palm Beach, FL) with bovine serum albumin (BSA) as a
standard.
2.6. DHR 123 and picogreen ﬂow cytometric and ﬂuorometric assays
Fresh ileum was homogenized by thorough crushing through a
steel mesh. Homogenized samples were processed for evidence of
oxidative stress in cellular and cell fragments (Total) through
DHR123 staining using di-hydro-rhodamine 123 (DHR 123, Invi-
trogen, Grand Island, NY) in accordance with manufacturer
instructions. Peritoneal lavage and blood were centrifuged at
300g for 5 min at 4 1C to separate plasma and extracellular ileum
and lavage ﬂuids (supernatant) from cells and unwanted debris
(pellet). The supernatants that contain the presumptive NETs were
analyzed for NETs with Quanti-iT PicoGreen dsDNA (Invitrogen) in
accordance with manufacturer instructions. Flow cytometric quan-
tiﬁcation and microscopic visualization were performed using BD
FACSAria ﬂow cytometer and Nikon Eclipse TE2000-S Inverted
Fluorescent Microscope, respectively.
2.7. In vitro NETosis
Neutrophils were isolated from fresh circulating blood using
Easy Sep Negative Selection Mouse Enrichment Kit (Stem Cell
Technologies, Vancouver, BC, CA) and ran through the Easy Sep
Magnet apparatus (Stem Cell Technologies) according to the
manufacturer instructions. Freshly isolated neutrophils were
placed in ﬂow cytometer tubes (Falcon round-bottom polystyrene
tubes; BD Biosciences, Franklin Lakes, NJ) and incubated with PE-
Cy7 tagged Gr-1 antibody (BioLegen, San Diego, CA) and Picogreen
(Quanti-iT PicoGreen dsDNA, Invitrogen) for 1 h then analyzed on
the BD FACSAria ﬂow cytometer immediately before and after
stimulation with 100 ng/mL of LPS (Sigma-Aldrich) (Time 0)
followed by real-time analysis over 1 h intervals. Flow cytometry
data was further analyzed with FCS Express 3.0 (DeNovo, Los
Angeles, CA).
2.8. Transepithelial electrical resistance (TEER) and FITC-Dextran-40
kD leakiness
Fresh one-centimeter sections of fresh terminal ileum were
mounted to a USSING diffusion chamber ﬁlled with Krebs–Hense-
leit buffer (Sigma-Aldrich) on both sides. The transepithelial
electrical resistance was measured with EVOM2 Epithelial Volt-
meter (World Precision Instruments). The true resistance was
calculated by ResistanceTrue (Ω)equal;ResistanceTotal (Ω) – Resis-
tanceKrebs–Henseleit buffer (Ω). The TEER was further calculated by
TEER (Ω cm2)equal;ResistanceTrue (Ω). Effective membrane area
(cm2).
In parallel experiments, the apical side of the USSING diffusion
chamber was ﬁlled with 50 mg/mL of FITC-Dextran-40 kD in
Krebs–Henseleit buffer (Sigma-Aldrich) and the basal side was
ﬁlled with blank Krebs–Henseleit buffer, then solution in the
apical side was sampled every 15 min for 4 h. Alternatively, fresh
terminal ileum sacs (1 cm long) were ﬁlled with 50 mg/mL of
FITC-Dextran-40 kD (Sigma-Aldrich) solution and ligated in an
everted gut sac method. The everted gut sacs were cryosectioned
into 30 mm ultra sections, viewed with TE2000-S Inverted Fluor-
escence Microscope, and analyzed with Metamorph digital ima-
ging software.
Moreover, parallel in vivo and in vitro permeability measure-
ments were assessed. In vivo leakiness was assessed by intra-
gastric gavage of 0.1% FITC-dextran 24 h before sacriﬁcing the rats
and measuring ﬂuorescence in circulating blood. In vitro perme-
ability was assessed by quantitative densitometric analysis of
ﬂuorescence levels in macrographic images of intestinal ileum
sac ﬁlled with FITC-dextran-S40 (M. wt, 40 K) and photographed
by a macro-imaging ﬂuorescence setup (Light Tools, CA) at times 0,
4, and 24 h.
2.9. Statistical data analysis
Data was analyzed using SPSS Statistics v. 21 (IBM, Armonk,
NY). One-way ANOVA and Tukey’s HSD post-hoc analysis was used
for most measurements. Student’s t-test was used for the oxidative
stress (protein oxidation, myeloperoxidase (MPO), Gr-1) assays.
Linear regression was used to describe the formation of NETs
(NETosis) relative to neutrophil oxidative state. A value of plt;0.05
was considered statistically signiﬁcant.
3. Results
3.1. Evidence for simvastatin's anti-inﬂammatory actions using
multiple classic markers of oxidative stress: Protein carbonylation,
myeloperoxidase (MPO), and Gr-1 levels
We ﬁrst examined alteration in the overall oxidant levels using
global protein carbonylation as a marker revealed by slot blotting
of total ileum mucosal protein isolate followed by Western blot
detection utilizing a monoclonal antibody for carbonyl reactive
groups. As shown in Fig. 1A inset, levels of protein carbonylation
appear substantially higher in the untreated TI group relative to
control or TIþSMV group. The inset was juxtaposed on a histo-
gram of quantitative densitometry measurements demonstrating
that the TI group sustained a massive increase in oxidation levels
(*, po0.05, Nequal;5, T-test) relative to control and that simvas-
tatin treatment (TIþSMV) protected against tissue oxidation to a
level below that of control (#, po0.05, Nequal;5, T-test).
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Moreover, the lower variability among simvastatin-treated sub-
jects suggests that simvastatin also eliminated the individual
natural subject variability in levels of tissue oxidation. Similarly,
Fig. 1B demonstrates that simvastatin treatment signiﬁcantly
decreased myeloperoxidase (MPO) activity as measured using a
colorimetric assay (po0.05, Nequal;5, T-test). Here again, the
simvastatin treatment group (TIþSMV) had much less variability
than the untreated TI group. The fact that MPO activity which is
linked to neutrophil inﬁltration was not decreased to the same
degree as protein oxidation may be linked to the presence of
sources of tissue oxidation other than neutrophils. Because mye-
loperoxidase activity was signiﬁcantly suppressed by simvastatin,
we decided to focus on neutrophils as a possible target for
simvastatin anti-inﬂammatory actions. For the same reason, we
decided to use melatonin as a positive control since our previous
work demonstrated that neutrophils are a major target for
melatonin anti-inﬂammatory actions in the mucosa barrier milieu
following major burn injury. Finally, Fig. 1C demonstrates that
simvastatin treatment (TIþSMV) signiﬁcantly truncates Gr-1
levels relative to untreated TI. Here, Gr-1 was visualized immuno-
histochemically in situ within sample terminal ileum villi and
immunopositive Gr-1 labeling appears in the form of
ﬂuorescently-labeled cells and exocytosed subcellular fragments
or NETs. Thus, in vivo postburn simvastatin treatment (TIþSMV)
substantially lowers oxidation (Fig. 1A) and neutrophil mediated
MPO (Fig. 1B) and Gr-1 levels (Fig. 1C ) in the terminal ileum tissue
and its biochemical preparations relative to their untreated ther-
mally injured (TI) counterparts.
3.2. Automated ﬂow cytometric analysis of NETosis
Levels of NETs are difﬁcult to quantify objectively by micro-
scopy because they tend to be diffusely scattered and/or tethered
to neutrophils (Fig. 1C). Therefore we sought for a quantitative
relationship between neutrophil activation and production of NETs
(NETosis) with ﬂuorescent Gr-1 immunohistochemistry as a sur-
rogate biomarker. Using the ﬂow cytometry gates demonstrated in
of the scatter plot of Fig. 2A, it is possible to quantify neutrophils
by their high granularity and henceforth large side scatter (SSC)
and high Gr-1 immunoﬂuorescence intensity as is the case in the
top right quadrant. On the other hand, Fig. 2B demonstrates the
gate for NETs based on their small size and henceforth small
forward scatter (FSC) and high Gr-1 immunoﬂuorescence intensity
as is the case in the top left quadrant. Using these settings, it is
possible to run automated measurements of neutrophils and NETs.
Fig. 2C and D demonstrates parallel progressive linear relation-
ships in the intracellular granularity of activated neutrophils
(Fig. 2C) and the levels of supernatant NETs produced in the
milieu wherein they are activated (Fig. 2D). As expected, TI
neutrophil granularity and the amount of NETs they produce have
progressed at higher rate in TI than those for control; speciﬁcally,
the TI neutrophil slope was about double of that for control and
the NETs TI slope was quadruple that of control. Thus, ﬂow
cytometry provides a novel automated quantiﬁcation of NETosis
that is more reliable than microscopy alone.
3.3. Evidence for simvastatin’s anti-inﬂammatory actions using ﬂow
cytometric and microscopic methods with multiple body ﬂuids.
3.3.1. Gr-1 ﬂow cytometry and microscopy
Fig. 3 uses ﬂow cytometry methods to quantitatively verify the
effects of simvastatin on neutrophil and NETs levels in gut tissue and
in body ﬂuid compartments that are hemodynamically relevant to it,
namely, general blood circulation and the peritoneal cavity. The gating
strategy detailed in Fig. 2A and B was also used here with neutrophils
being gated based on Gr-1 immunoﬂuorescence alongside high
granularity while NETs being gated based on Gr-1 immunoﬂuores-
cence combined with small, cellular-fragment sizes. In all cases,
ﬂuorescence intensity and counts were veriﬁed microscopically;
Fig 1. Anti-inﬂammatory effects of postburn in vivo simvastatin treatment as
demonstrated in terminal ileum epithelium with assays for total protein carbonyla-
tion and Gr-1 immunolabeling as well as myeloperoxidase (MPO) activity.
(A) Protein carbonylation. There was a signiﬁcant 30% more carbonyl immuno-
labeling intensity for total protein isolated from thermal injury (TI) relative to
control subjects (*, P o 0.05, N ¼ 5, T-test). Simvastatin treatment signiﬁcantly
decreased this hyperoxidation down to or below control levels (#, P o 0.05, N¼ 5,
T-test). (B) Myeloperoxidase activity. Average MPO activity in TI intestinal tissue
homogenates was signiﬁcantly increased to about double that in control tissue (*, P
o 0.05, N ¼ 4, T-test). Simvastatin treatment (TI þ SMV) was associated with a
signiﬁcant decrease in MPO activity to almost half its TI levels, thus indicating
simvastatin’s protective effect against neutrophil inﬁltration (#, P o 0.05, N ¼ 4, T-
test). (C) Gr-1 immunohistochemistry. Representative micrographs demonstrating
substantially higher Gr-1 immunohistochemical labeling in unmedicated thermal
injury (TI) relative to the control (CT) subjects. This elevated Gr-1 immunolabeling
consisted of cellular and cellular fragment elements (inset) indicative of neutrophil
inﬁltration and NETosis. Postburn in vivo simvastatin treatment (TI þ SMV)
treatment was associated with a substantial decrease in GR-1 labeling that was
comparable to that with melatonin treatment (TI þ Mel).
Fig 2. Flow cytometric analysis of postburn neutrophil hyperinﬂammation. A and
B. Gating neutrophils versus NETs. (A) Gr-1-PE-CY7 immunolabeling intensity was
plotted against side scatter (SSC) as an indicator of granularity. Here, the gate for
neutrophils is in the upper-right quadrant because of their high granularity and
high PE-CY7-linked Gr-1 immunolabeling intensity. (B) FITC ﬂuorescence of pico-
green labeling was plotted against forward scatter (FSC). Here, the gate for NETs is
in the upper-left quadrant associated with high FITC green signal picogreen
ﬂuorescence and the low FSC of tiny sized cell-fragment that deﬁnes NETs. (C
and D) Control versus TI neutrophil real-time response to in vitro lipopolysaccharide
(LPS) stimulation as measured by ﬂow cytometry. In all control and TI neutrophil
samples examined, relative numbers (%) of activated neutrophils and emerging
picogreen positive NETs progressed in a linear fashion during the period of
measurement (p o 0.05). As indicated by the slopes of the linear regression
curves, thermal injury doubled the rate of Gr-1 (C) and quadrupled the rate of
NETosis (D) in response to LPS in comparison to control.
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sample micrographs are shown juxtaposed on ileum and peritoneal
lavage histograms (Fig. 3). As shown in Fig. 3A, both simvastatin
(TIþSMV) and melatonin (TIþMel) exhibit profound anti-
inﬂammatory effects in ileum and colon mucosae relative to the
excessive neutrophil- and NETs-inﬁltrations seen in untreated TI.
Interestingly, the control proximal ileum appeared more inﬂamed
than proximal ileum and thermal injury caused relatively more
inﬂammation in the proximal colon (about 3–4 times increase) than
in the terminal ileum (about 2–3 times increase), but simvastatin had
more powerful ability to truncate ileum inﬂammation by decreasing it
by about 75% than colon inﬂammation which it brought down by
around 50%. These differences notwithstanding, the protective anti-
inﬂammatory effects of postburn simvastatin and melatonin were
statistically signiﬁcant in both cases (#, Nequal;3, po0.05, One-way
ANOVA). Fig. 3B shows NETosis measurements in samples of plasma
from general blood circulation and peritoneal lavage (Fig. 3B) are in
line with those from ileum and colon tissue milieu (Fig. 3A) and are
henceforth equally good indicators of the inﬂammatory state. Inter-
estingly, peritoneal lavage TI NETosis levels were in par with those of
colon, about double those in ileum and almost an order of magnitude
over those in plasma which may be a function of the higher level of
neutrophil effector function upon extravasation in the colon and
peritoneal microenvironments. Nevertheless, the lower levels of
NETosis detected in blood was not only consistent with the lower
bowel mucosa interstitial milieux tested here but also reﬂected the
appropriate level of statistical signiﬁcance.
3.3.2. DHR123 ﬂow cytometry and microscopy
Here and in section 3.3.3 (below), DHR123 and picogreen were
utilized as additional surrogate biomarkers for NETosis using the
same gating strategy as Fig. 2A and B and the relevant ﬂuorescence
channels. Table 1 shows detailed raw DHR 123 data from various
body ﬂuids and compartments, namely, intestinal interstitium
(ileum and colon) as well as general blood circulation and
peritoneum. In all cases, simvastatin and melatonin treated sub-
jects exhibited substantial suppression in oxidative stress-linked
DHR 123 labeling regardless of the body ﬂuid compartment
assessed (po0.01–0.05, N¼3–9). This suppression was uniformly
consistent across body ﬂuid compartments and regardless of the
method of quantiﬁcation: microscopic manual counts, microscopic
automated microdensity and count measurements, and ﬂow
cytometry automated analysis.
3.3.3. Picogreen ﬂow cytometry and microscopy
Table 2 also shows detailed picogreen data from various body
ﬂuids and compartments, namely, intestinal interstitium (ileum
and colon) as well as general blood circulation and peritoneum. In
all cases, simvastatin and melatonin treated subjects exhibited
substantial suppression in neutrophil htperactivation-linked posi-
tive cell-free dsDNA or NETs labeling regardless of the body ﬂuid
compartment assessed. In the blood plasma, there was over a 100%
increase with TI and approximately 50% decrease with both
treatments of melatonin and simvastatin (plt;0.05, One-way
ANOVA, Nequal;4–8). In the peritoneal lavage, there was a 90%
decrease with TIþMel (plt;0.03, One-way ANOVA, Nequal;4–6). In
the colon, there was an increase of over 2.5-fold with TI and
decrease of 65% with TIþMel and over half with TIþSMV (plt;0.04,
One-way ANOVA, Nequal;4–8). Similarly, the ileum had a doubling
with TI and over 70% decrease with both TIþMel and TIþSMV
(plt;0.04, One-way ANOVA, N ¼ 4–7).
The Picogreen positive manual counts and automated measure-
ments of relative ﬂuorescence intensity were positively correlated (r2
 0.94, plt;0.01, Nequal;3). With the manual quantiﬁcations in blood
and peritoneal lavage, there was a TI-induced increase by 2-fold and
Fig 3. Anti-inﬂammatory effects of postburn in vivo simvastatin treatment as
demonstrated by ﬂow cytometric analysis of NETosis in supernatants of terminal
ileum and colon mucosa scraping homogenates (A) as well as heparinized systemic
blood and peritoneal lavage samples (B). In all cases, Gr-1 immunolabeling
ﬂuorescence labeling intensity exhibited a signiﬁcant two- to ﬁve- increase in
unmedicated TI (*, N ¼ 4, p o 0.05, T-test) relative to control subjects indicating
excessive Gr-1 levels that traversed body ﬂuid compartments with highest signal
intensities in peritoneal lavage and colon (800 relative ﬂuorescence units, RFU’s),
followed by ileum (400 RFU’s), then systemic blood (130 RFU’s). In each of
these extracellular ﬂuid compartments, all samples from postburn in vivo simvas-
tatin treatment (TI þ SMV) subjects exhibited a substantial decrease in Gr-1
immunolabeling signal down to or below control levels. Such anti-inﬂammatory
action by simvastatin was consistently comparable to that with melatonin treat-
ment (TI þ Mel) with the actions of both drugs being statistically signiﬁcant (#, N
¼ 4, p o 0.05, One-way ANOVA). Automated ﬂow cytometric analysis was visually
veriﬁed by microscopy as depicted in micrographs juxtaposed on the ileum and
peritoneal lavage histograms.
Fig 4. Effect of in vivo simvastatin postburn treatments on gut permeability as
measured in terms of (A) ex vivo transepithelial leakiness to FITC-labeled dextran-
40 and (B) transepithelial electrical resistance (TEER). (A) The relative level of
transepithelial FITC-Dextran-40 diffusion was signiﬁcantly higher by over 10–30%
relative to control as measured across ileum (left) and colon (right) walls
(respectively) ex vivo utilizing a USSING diffusion chamber (*, N ¼ 5, p o 0.05,
One-way ANOVA). In both ileum and colon samples, simvastatin (TI þ SMV)
achieved similar results to melatonin (TI þ Mel) as both of them suppressed gut
leakiness to below control levels (#, N ¼ 5, p o 0.02, One-way ANOVA). (B) The
relative level of TEER in ileum (left) and colon (right) underwent similar patterns of
change with about one-tenth decrease in TEER or increase in leakiness as measured
across the entire wall of the intestine ex vivo utilizing a USSING diffusion chamber
(*, N ¼ 5, p o 0.05, One-way ANOVA, N ¼ 3). In both ileum and colon samples,
simvastatin (TI þ SMV) achieved slightly better results than melatonin (TI þ Mel)
as it narrowed the leakiness gap relative to control by about 50% (#, N ¼ 5, p o
0.05, One-way ANOVA, N ¼ 3).
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treatment-mediated decrease by almost 70% (plt;0.01, Nequal;3).
Within the gut, there was also a doubling with TI and a lowering of
about 60% in the colon and over 70% in the ileum (plt;0.01, Nequal;3).
With the automated quantiﬁcations in the blood and peritoneal lavage,
there was well over a one-third increase with TI and a decrease of over
a 15% in the blood and a one-fourth in the peritoneal lavage (plt;0.01).
Similarly, the colon had a 30% increase with TI and close to 15%
decrease with both TIþMel and TIþSMV (plt;0.01, Nequal;3). The
ileum had a 50% increase with TI and around a 25% decrease with both
TIþMel and TIþSMV (plt;0.01, N ¼ 3).
3.4. FITC-Dextran-40 kD leakiness and TEER
As shown in Fig. 4A, transepithelial FITC-Dextran-40 kD leakiness
was about 20–30% higher in TI ileum and colon than control and that
melatonin and simvastatin treatments brought leakiness down to
below its control levels. This was conﬁrmed by microscopy which
revealed much more FITC green ﬂuorescence diffusion throughout
ileum and colon walls of untreated major TI subjects relative to their
control, TIþMel, and TIþSMV counterparts.
This preventative effect of simvastatin and melatonin against TI
triggered gut leakiness was conﬁrmed by TEER measurement. As
shown in Fig. 4B, there was a signiﬁcant drop in resistance of
10% in TI relative to control, about a quarter to a third of which
was protected by melatonin and over one half by simvastatin
(plt;0.05, One-way ANOVA, Nequal;3). The difference in measure-
ments relative to diffusion data may be attributed to the fact that
the TEER values were measured across the entire colon and ileum
walls, not just the epithelium layer and that TEER measurements
take much less time (minutes) while the tissue is still much
fresher while diffusion data take longer (hours).
Further conﬁrmation of simvastatin’s protective effect against
gut leakiness associated with thermal injury was carried out by
comparing untreated versus simvastatin major TI subjects in terms
of in vivo leakiness assessed by gastric gavage followed by FITC-
dextran and ex vivo leakiness of FITC-dextran ﬁlled gut sacs. These
measurements demonstrated as much as 60% (in vivo, Nequal;4)
and 80% (ex vivo, Nequal;4) suppression by simvastatin.
Thus, all the methods used herein conﬁrm a strong protective
effect for simvastatin and melatonin against major postburn gut
Table 1
DHR 123 ﬂow cytometric and ﬂuoromicrographic assay. The change between TI and each of the other groups was statistically signiﬁcant in all the body ﬂuid compartments
examined (p o 0.01–0.05, N ¼ 4–8).
Method of quantiﬁcation Treatment
CT TI TI þ Mel TI þ SMV
Flow cytometry
Blood 3.94 7 1.84 12.06 7 5.24 1.26 7 0.10 3.15 7 1.00
Peritoneal lavage 3.79 7 0.24 8.87 7 2.73 2.35 7 0.59 4.14 7 0.65
Colon 62.90 7 14.08 153.76 7 47.44 66.96 7 16.02 39.86 7 9.97
Ileum 132.10 7 12.60 1169.64 7 23.90 58.2 7 27.04 91.80 7 45.93
Fluorescent microscopy
Cell count
Blood 5.67 7 0.67 16.67 7 1.67 6.33 7 0.33 8.00 7 0.58
Peritoneal lavage 5.33 7 0.33 13.67 7 0.88 5.00 7 0.58 6.67 7 0.67
Colon 16.33 7 0.88 28.33 7 2.33 20.67 7 1.20 22.67 7 0.88
Ileum 20.67 7 1.20 42.33 7 1.20 23.33 7 1.67 23.00 7 2.31
Fluorescence
Blood 45.41 7 2.74 72.34 7 1.22 54.47 7 2.25 54.28 7 1.67
Peritoneal lavage 46.40 7 1.82 72.34 7 1.56 56.65 7 2.55 56.76 7 3.14
Colon 47.28 7 1.90 75.58 7 1.01 59.88 7 0.38 63.70 7 0.36
Ileum 43.09 7 1.76 71.03 7 0.91 61.95 7 2.05 62.41 7 1.64
Table 2
Picogreen ﬂow cytometric and ﬂuoromicrographic assay. The change between TI and each of the other groups was statistically signiﬁcant in all the body ﬂuid compartments
examined (p o 0.01–0.05, N ¼ 4–8).
Method of quantiﬁcation Treatment
CT TI TI þ Mel TI þ SMV
Flow cytometry
Blood 68.37 7 17.61 137.91 7 12.57 62.73 7 21.51 71.81 7 15.95
Peritoneal lavage 224.27 7 95.37 1049.10 7 320.39 101.12 7 25.72 298.29 7 121.56
Colon 244.70 7 72.71 901.08 7 195.74 310.52 7 74.59 429.28 7 93.97
Ileum 153.55 7 56.83 411.09 7 320.39 83.31 7 46.25 112.18 7 29.23
Fluorescent microscopy
Cell count
Blood 2.33 7 0.33 7.67 7 0.67 2.33 7 0.33 2.33 7 0.33
Peritoneal lavage 9.33 7 0.67 32.00 7 1.53 11.33 7 0.88 10.67 7 0.67
Colon 11.33 7 0.33 32.33 7 1.45 12.67 7 0.33 13.33 7 0.33
Ileum 6.67 7 0.33 23.33 7 1.20 7.00 7 0.58 5.67 7 0.33
Fluorescence
Blood 55.99 7 0.92 74.68 7 2.28 62.58 7 0.52 62.12 7 1.03
Peritoneal lavage 52.91 7 1.38 73.23 7 1.80 54.66 7 0.65 53.33 7 1.19
Colon 55.00 7 1.33 71.39 7 0.25 60.10 7 0.74 62.09 7 0.72
Ileum 54.49 7 2.25 80.09 7 0.97 62.48 7 0.83 59.41 7 0.31
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leakiness, albeit with slight variation in the degree of protection
based on the method used. Speciﬁcally, TEER and in vivo FITC-
dextran leakiness measurements demonstrated partial protection
by simvastatin while ex vivo FITC-dextran diffusion data showed
that simvastatin treatment improved leakiness to below sham
levels. This variation maybe attributed to possible in vivo versus
ex vivo differences in tissue versus systemic dynamic factors
converging at the level of the gut barrier and/or handling dextran,
alongside natural variations in gut tissue inﬂammation [39].
4. Discussion
Our results show that treatment with simvastatin has similar
tissue-speciﬁc and systemic therapeutic effects to treatment with
melatonin when administered in vivo immediately and 24 h
following major thermal injury. Speciﬁcally, immediate postburn
simvastatin and melatonin treatments where associated with
decreased neutrophil-mediated inﬂammation, NETosis, and gut
leakiness relative to untreated subjects. These effects were evi-
denced by profoundly lower levels of the following: (1) gut
mucosa protein oxidation and neutrophil inﬁltration (Figs. 1 and
3 and Tables 1 and 2), (2) NETs in circulating plasma, peritoneal
lavage, and ileum as well as colon mucosa (Fig. 3 and Tables 1 and
2), and (3) gut mucosa permeability (Fig. 4) in simvastatin- and
melatonin-treated TI mice relative to their untreated TI litter-
mates. From a diagnostic perspective, our results also show that
NETosis follows a linear regression relative to neutrophil activity
(Fig. 2) and that levels of NETs in systemic blood parallel those in
terminal ileum and proximal colon, albeit at much lower concen-
trations (Fig. 3, Tables 1 and 2). Following is a discussion of our
ﬁndings in the context of relevant literature in the areas of
simvastatin and inﬂammation, simvastatin and gut barrier func-
tion and sepsis, and the use of NETs as a diagnostic inﬂammation
marker.
4.1. Simvastatin and inﬂammation
Our results are in agreement with mounting evidence in
support of simvastatin’s anti-inﬂammatory actions. This includes
Pruefer et al.'s [10] investigation of intestinal microcirculation
showing that simvastatin pretreatment not only attenuates neu-
trophil's exotoxin-induced rolling and adherence as well as
endothelial P-selectin expression but it also profoundly suppresses
neutrophil transmigration [10]. This protective effect by simvasta-
tin against neutrophil transmigration is in clear agreement with
decreases in tissue neutrophil and MPO levels observed in Fig. 1.
Similar ﬁndings were reported by Diomede [11] and Maher [5]
who also showed that simvastatin inhibits acute and chronic
inﬂammatory responses by interfering with endothelial adhesion
and leukocyte migration to sites of inﬂammation [5,11]. Aside from
the supportive mechanistic similarity between these reports and
ours, our work brings about two advances, namely, targeting gut
mucosa pathogenesis following major thermal injury with its
multifaceted pathological dynamics [1,1321], and devising an
in vivo post-injury treatment regimen and in comparison with
our previously published melatonin observations in the same
model as a positive control [1].
Mechanistically, the ability of simvastatin to block neutrophil’s
endothelial adhesion and transmigration is integral to our central
hypothesis that simvastatin has protective therapeutic effects
against early postburn gut mucosa inﬂammation and leakiness
especially in the context of assessing NETs as a surrogate diag-
nostic biomarker for postburn gut inﬂammation. This is in accor-
dance with a plethora of expected beneﬁts for utilizing statins in
targeting the complex inﬂammatory major postburn gut barrier
milieu based on converging recent ﬁndings in the ﬁeld [5–12,38–
41]. Reported mechanisms for such beneﬁcial simvastatin actions
include the following: (1) inhibiting the expression of speciﬁc cell
surface receptors on monocytes, adhesion molecules and also
integrin-dependent leukocyte adhesion and reducing inﬂamma-
tory markers such as C-reactive protein [40], (2) promoting the
anti-inﬂammatory cytokine IL-10 synthesis and decreasing pro-
inﬂammatory cytokines such as IL-6, IL-23p19, IFN-γ, TNF-α, IL-6,
MCP-1 [40,41], (3) enhancing potent antioxidant effects through
myeloperoxidase-, nitric oxide-, NFκB-, and glutathione-linked
mechanisms [6,7,42,43], (4) inhibiting the induction of the major
histocompatibility (MHC) class II expression by interferon-gamma
(IFN-gamma), leading to repression of MHC II-mediated T-cell
activation [40], and (5) changing the regional tissue speciﬁc
modulation of glucose metabolism [44] and suppression of TNF-
α and caspase-3 expression [45].
4.2. Simvastatin and gut barrier function and sepsis
Our observation of simvastatin’s ability to protect against major
postburn leakiness is in agreement with its reported ability: (1) to
ameliorate immunopathology in an acute rat model of colitis with
normal blood cholesterol levels through mechanisms that involve
blocking neutrophil accumulation in the small intestine and low-
ering serum TNF-α levels [42], (2) to prevent parasite-induced
barrier-compromise, suggesting a therapeutic potential of statins
in intestinal infections [46], and (3) to suppress bacterial translo-
cation across the Madin-Darby canine kidney (MDCK) cell mono-
layers in vitro [47].
Similarly, there is accumulating evidence in regards to statins’
protective effects in relevant cases of shock, trauma, and sepsis.
This includes statin’s ability to (1) modulate microvascular
endothelium and/or leukocyte interactions that are implicated in
mechanisms of inﬂammation, such as iNOS expression, cytokine
production, and cell adhesion molecules on both endothelial cells
and leukocytes [48], (2) reduce septic shock and signiﬁcantly
decrease mortality in a retrospective study of elderly burn patients
who received statin treatment prior to injury burns [49], (3) appear
to signiﬁcantly reduce mortality in patients who received statin
treatment prior to the development of severe sepsis compared
with patients that were not treated with statins [50], and
(4) reduce multiple organ dysfunction and peritonitis in an
experimental model of zymosan-induced multiple organ failure
through anti-inﬂammatory mechanisms that involve PPARα [51].
In conclusion, the totality of our ﬁndings supports a strong
beneﬁcial effect for simvastatin in suppressing early postburn gut
inﬂammation and gut leakiness in the mouse experimental model
of burn injury within the limits of our treatment and dosing
regimens. However, our data also includes slight variations in the
degree of simvastatin protective effect on gut permeability that
may be attributed to methodological or natural variation [39].
More work is needed to fully assess the full spectrum of statins’
pleiotropic actions within and outside the gut. This includes
statins’ reported undesirable effects of precipitating myopathy in
up to 13% of the human patients surveyed [52].
4.3. NETs as a diagnostic inﬂammation marker
Our results revealed that NETosis follows a linear regression
relative to neutrophil activity levelsin vitro (Fig. 2) with LPS-
stimulated neutrophils from thermally injured mice undergoing
a four-fold increase in rate of NETosis relative to those from sham
mice (Fig. 2D). This increase in TI neutrophil NETosis levels in vitro
was mirrored by heightened in vivo levels of NETs in gut mucosa
interstitial ﬂuid, peritoneal lavage, and circulating blood (Fig. 3,
Tables 1 and 2). This consistency of NETosis in our TI and sham
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data from in vivo and in vitro preparations and across body ﬂuid
compartments supports the notion that NETs traverse body ﬂuid
compartments. Furthermore, the fact that circulating plasma levels
of NETs also mirror classic tissue markers of inﬂammation (Fig. 1),
as well as gut permeability, suggests that sampling circulating
plasma may be a good indicator of tissue inﬂammation state. At
ﬁrst glance, peritoneal lavage appears to be a better indicator of
gut mucosa tissue inﬂammatory state especially that TI colon NETs
levels appear to be almost identical in magnitude with those of the
TI peritoneal lavage (mean relative ﬂuorescence of 1000, Fig. 3)
which is about an order of magnitude higher than plasma levels
(mean relative ﬂuorescence of just over 100, Fig. 3). However, the
fact that peritoneal lavage in our experiments represents extra-
vasated neutrophils associated with thioglycolate stimulation
indicates that thioglycolate-aggravated peritoneal neutrophils
should possess the identity of tissue neutrophils such as those of
the TI colon and should henceforth rival it in terms of reaching the
highest inﬂammatory state and indeed NETs levels [13]. Contra-
riwise, plasma NETs represent the sum of NETs that passively leak
from inﬂamed compartments due to increased vascular leakiness
(which is reported to be higher in TI subjects) alongside those
released by circulating neutrophils especially those activated by
neurotoxin and/or bacteria entering the general circulation due to
gut leakiness [17–21]. This would be further compounded by the
higher NETosis levels of TI (TI/Control slope ratioequal;2.2, Fig. 2C)
relative to control neutrophils (TI/Control slope ratioequal;4.5,
Fig. 2D).
Combined with the ease of peripheral blood sampling, the ease
of measurement of NETs by ﬂuorescent techniques with picogreen,
Gr-1 and/or DHR123, represents a quick and easy alternative to
classic tissue markers and DNA isolation combined with quanti-
tative PCR. If standardized, such alternative is expected to facilitate
appropriate treatment modules for major burn injury which are
currently hampered by lack of accurate prediction of prognosis in
burn patients [53]. It may also be combined with current pre-
dictors of morbidity and mortality such as abbreviated burn
severity index (ABSI) scoring system based on pathophysiological
measures and chemical analyses as well as the estimation of
inﬂammation and severity of burn by markers such as pro-
calcitonin (PCT), C-reactive protein (CRP), and interleukin (IL)-6
[53–59]. Such diagnostic use would expand the role of NETs
beyond its initial standing as a byproduct of neutrophil activation
and its current standing as a major neutrophil immune effector
function alongside phagocytosis and oxygen burst to solidify their
emerging diagnostic value [22,60]. Indeed, recent evidence sup-
ports a high predictive value of NETs in assessing the risk of
multiple trauma patients to develop sepsis and to die [26,27,29].
This is because circulating free DNA is quite likely the result of
multiple cell sources during tissue damage and inﬂammation. On
the other hand, the fact that NETs also harbor intracellular
components makes them a source of further autoimmune patho-
physiology especially if produced excessively and left unchecked
[24,25,33–36].
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